| Style | Citing Format |
|---|---|
| MLA | Solaymanidodaran M, et al.. "Safety and Efficacy of Favipiravir in Moderate to Severe Sars-Cov-2 Pneumonia." International Immunopharmacology, vol. 95, no. , 2021, pp. -. |
| APA | Solaymanidodaran M, Ghanei M, Bagheri M, Qazvini A, Vahedi E, Hassan Saadat S, Amin Setarehdan S, Ansarifar A, Biganeh H, Mohazzab A, Khalili D, Hosein Ghazale A, Reza Heidari M, Taheri A, Khoramdad M, Mahdi Asadi M, Nazemieh M, Varshochi M, Abbasian S, ... Moazen J (2021). Safety and Efficacy of Favipiravir in Moderate to Severe Sars-Cov-2 Pneumonia. International Immunopharmacology, 95(), -. |
| Chicago | Solaymanidodaran M, Ghanei M, Bagheri M, Qazvini A, Vahedi E, Hassan Saadat S, Amin Setarehdan S, et al.. "Safety and Efficacy of Favipiravir in Moderate to Severe Sars-Cov-2 Pneumonia." International Immunopharmacology 95, no. (2021): -. |
| Harvard | Solaymanidodaran M et al. (2021) 'Safety and Efficacy of Favipiravir in Moderate to Severe Sars-Cov-2 Pneumonia', International Immunopharmacology, 95(), pp. -. |
| Vancouver | Solaymanidodaran M, Ghanei M, Bagheri M, Qazvini A, Vahedi E, Hassan Saadat S, et al.. Safety and Efficacy of Favipiravir in Moderate to Severe Sars-Cov-2 Pneumonia. International Immunopharmacology. 2021;95():-. |
| BibTex | @article{ author = {Solaymanidodaran M and Ghanei M and Bagheri M and Qazvini A and Vahedi E and Hassan Saadat S and Amin Setarehdan S and Ansarifar A and Biganeh H and Mohazzab A and Khalili D and Hosein Ghazale A and Reza Heidari M and Taheri A and Khoramdad M and Mahdi Asadi M and Nazemieh M and Varshochi M and Abbasian S and Bakhtiari A and Mosaed R and Hosseinishokouh SJ and Shahrokhi M and Yassin Z and Ali Zohal M and Qaraati M and Rastgoo N and Sami R and Javad Eslami M and Asghari A and Namazi M and Ziaie S and Jafarimoghaddam R and Kalantari S and Memarian M and Khodadadi J and Hossein Afshari M and Momenheravi M and Behzadseresht N and Reza Mobayen A and Mozafari A and Movasaghi F and Haddadzadeh Shoushtari M and Moazen J}, title = {Safety and Efficacy of Favipiravir in Moderate to Severe Sars-Cov-2 Pneumonia}, journal = {International Immunopharmacology}, volume = {95}, number = {}, pages = {-}, year = {2021} } |
| RIS | TY - JOUR AU - Solaymanidodaran M AU - Ghanei M AU - Bagheri M AU - Qazvini A AU - Vahedi E AU - Hassan Saadat S AU - Amin Setarehdan S AU - Ansarifar A AU - Biganeh H AU - Mohazzab A AU - Khalili D AU - Hosein Ghazale A AU - Reza Heidari M AU - Taheri A AU - Khoramdad M AU - Mahdi Asadi M AU - Nazemieh M AU - Varshochi M AU - Abbasian S AU - Bakhtiari A AU - Mosaed R AU - Hosseinishokouh SJ AU - Shahrokhi M AU - Yassin Z AU - Ali Zohal M AU - Qaraati M AU - Rastgoo N AU - Sami R AU - Javad Eslami M AU - Asghari A AU - Namazi M AU - Ziaie S AU - Jafarimoghaddam R AU - Kalantari S AU - Memarian M AU - Khodadadi J AU - Hossein Afshari M AU - Momenheravi M AU - Behzadseresht N AU - Reza Mobayen A AU - Mozafari A AU - Movasaghi F AU - Haddadzadeh Shoushtari M AU - Moazen J TI - Safety and Efficacy of Favipiravir in Moderate to Severe Sars-Cov-2 Pneumonia JO - International Immunopharmacology VL - 95 IS - SP - EP - PY - 2021 ER - |